IL251905B - Epilimod for use in the treatment of kidney cancer - Google Patents

Epilimod for use in the treatment of kidney cancer

Info

Publication number
IL251905B
IL251905B IL251905A IL25190517A IL251905B IL 251905 B IL251905 B IL 251905B IL 251905 A IL251905 A IL 251905A IL 25190517 A IL25190517 A IL 25190517A IL 251905 B IL251905 B IL 251905B
Authority
IL
Israel
Prior art keywords
apilimod
treatment
renal cancer
renal
cancer
Prior art date
Application number
IL251905A
Other languages
English (en)
Hebrew (he)
Other versions
IL251905A0 (en
Original Assignee
Ai Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ai Therapeutics Inc filed Critical Ai Therapeutics Inc
Publication of IL251905A0 publication Critical patent/IL251905A0/en
Publication of IL251905B publication Critical patent/IL251905B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
IL251905A 2014-11-07 2017-04-24 Epilimod for use in the treatment of kidney cancer IL251905B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462077127P 2014-11-07 2014-11-07
PCT/US2015/059512 WO2016073877A1 (en) 2014-11-07 2015-11-06 Apilimod for use in the treatment of renal cancer

Publications (2)

Publication Number Publication Date
IL251905A0 IL251905A0 (en) 2017-06-29
IL251905B true IL251905B (en) 2021-03-25

Family

ID=54548302

Family Applications (1)

Application Number Title Priority Date Filing Date
IL251905A IL251905B (en) 2014-11-07 2017-04-24 Epilimod for use in the treatment of kidney cancer

Country Status (16)

Country Link
US (3) US10206910B2 (enExample)
EP (2) EP3581184B1 (enExample)
JP (1) JP6705828B2 (enExample)
KR (1) KR20170098812A (enExample)
CN (1) CN107249638B (enExample)
AU (1) AU2015342869A1 (enExample)
BR (1) BR112017008799A2 (enExample)
CA (1) CA2966359A1 (enExample)
ES (1) ES2741399T3 (enExample)
HU (1) HUE044557T2 (enExample)
IL (1) IL251905B (enExample)
MX (1) MX377593B (enExample)
PL (1) PL3215158T3 (enExample)
PT (1) PT3215158T (enExample)
RU (1) RU2727802C2 (enExample)
WO (1) WO2016073877A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2015209133B2 (en) 2014-01-24 2019-10-03 AI Therapeutics, Inc. Apilimod compositions and methods for using same
ES2734081T3 (es) * 2014-11-07 2019-12-04 Ai Therapeutics Inc Apilimod para el uso en el tratamiento de melanoma
CN107249638B (zh) 2014-11-07 2021-05-14 人工智能治疗公司 阿匹莫德用于治疗肾癌
JP2019502707A (ja) * 2016-01-21 2019-01-31 ラム・セラピューティクス，インコーポレーテッド 癌をアピリモドで処置するためのバイオマーカー
MX2019002185A (es) * 2016-08-25 2019-09-19 Ai Therapeutics Inc Composiciones y metodos relacionados con la inhibicion de la señalizacion de rangos.
US20190365771A1 (en) * 2016-10-12 2019-12-05 AI Therapeutics, Inc. Apilimod compositions and methods for using same in the treatment of alzheimer's disease
EP3600328A4 (en) 2017-03-24 2021-01-06 3100 Central Expressway LLC MERGED TRIAZOLO-PYRIMIDINE COMPOUNDS WITH USEFUL PHARMACEUTICAL APPLICATION
US11524053B2 (en) 2018-01-26 2022-12-13 The Regents Of The University Of California Methods and compositions for treatment of angiogenic disorders using anti-VEGF agents
US12589097B2 (en) 2018-02-21 2026-03-31 OrphAl Therapeutics Inc. Apilimod compositions and methods of use
US10751345B2 (en) 2018-02-21 2020-08-25 AI Therapeutics, Inc. Combination therapy with apilimod and glutamatergic agents
CN114867487A (zh) 2019-11-25 2022-08-05 加利福尼亚大学董事会 用于眼内新生血管的长效vegf抑制剂
US12486274B2 (en) 2020-01-13 2025-12-02 Verge Analytics, Inc. Substituted pyrazolo-pyrimidines and uses thereof
CN114306370A (zh) * 2021-12-31 2022-04-12 北京悦康科创医药科技股份有限公司 反义寡核苷酸在制备治疗肾癌药物中的应用

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5210015A (en) 1990-08-06 1993-05-11 Hoffman-La Roche Inc. Homogeneous assay system using the nuclease activity of a nucleic acid polymerase
EP0728218B1 (en) 1993-11-12 2008-01-02 PHRI Properties, Inc. Hybridization probes for nucleic acid detection, universal stems, methods and kits
US6693097B2 (en) 2001-11-30 2004-02-17 Synta Pharmaceuticals Corp. Pyrimidine compounds
WO2005076843A2 (en) 2004-02-06 2005-08-25 Elan Pharmaceuticals, Inc. Methods and compositions for treating tumors and metastatic disease
TWI380816B (zh) 2004-04-13 2013-01-01 Synta Pharmaceuticals Corp 抑制介白素-１２（ｉｌ-１２）生成之二鹽抑制劑
JP2008512490A (ja) 2004-09-08 2008-04-24 チェルシー・セラピューティクス，インコーポレイテッド 異常細胞増殖および炎症の障害を治療するための代謝的に不活性な葉酸拮抗剤
TW200630363A (en) 2004-11-10 2006-09-01 Synta Pharmaceuticals Corp Process for preparing trisubstituted pyrimidine compounds
TW200720256A (en) 2005-05-13 2007-06-01 Synta Pharmaceuticals Corp IL-12 modulatory compounds
WO2006128129A2 (en) * 2005-05-26 2006-11-30 Synta Pharmaceuticals Corp. Method for treating cancer
CA2630271C (en) 2005-11-17 2014-04-08 Osi Pharmaceuticals, Inc. Fused bicyclic mtor inhibitors
AR057960A1 (es) 2005-12-02 2007-12-26 Osi Pharm Inc Inhibidores de proteina quinasa biciclicos
EP1981890A2 (en) 2006-01-25 2008-10-22 OSI Pharmaceuticals, Inc. UNSATURATED mTOR INHIBITORS
ES2780193T3 (es) 2006-07-12 2020-08-24 Univ Tennessee Res Found Compuesto para tratar el cáncer de mama y afecciones dependientes de la progestina
CA2675558A1 (en) 2007-02-06 2008-08-14 Novartis Ag Pi 3-kinase inhibitors and methods of their use
RU2438664C2 (ru) 2007-05-15 2012-01-10 Пирамал Лайф Сайнсиз Лимитед Синергическая фармацевтическая комбинация для лечения рака
DE102007036076A1 (de) * 2007-08-01 2009-02-05 Bayer Healthcare Aktiengesellschaft Dipeptoid-Produgs und ihre Verwendung
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
JP5258331B2 (ja) 2008-03-03 2013-08-07 ロート製薬株式会社 光安定性が改善されたニューキノロン系抗菌剤含有医薬組成物
US20110224223A1 (en) 2008-07-08 2011-09-15 The Regents Of The University Of California, A California Corporation MTOR Modulators and Uses Thereof
EP3023426A1 (en) 2008-07-17 2016-05-25 Critical Outcome Technologies, Inc. Thiosemicarbazone inhibitor compounds and cancer treatment methods
EP3338770B1 (en) 2010-03-08 2023-06-07 Sloan-Kettering Institute For Cancer Research Cdc7 kinase inhibitors and uses thereof
JP5783499B2 (ja) * 2010-03-29 2015-09-24 味の素株式会社 フェニルアラニン誘導体を含有する医薬製剤
US8402515B2 (en) 2010-05-06 2013-03-19 Jonathan Weizman Apparatus and method for establishing a peer-to-peer communication session with a client device
US20110287018A1 (en) 2010-05-19 2011-11-24 Philip Bosch Methods of Treating Interstitial Cystitis
US8709419B2 (en) * 2010-08-17 2014-04-29 Hoffmann-La Roche, Inc. Combination therapy
GEP201606545B (en) 2010-11-19 2016-09-26 Ecole Polytech 2-piperazin-1-yl-4h-1,3-benzo-thiazin-4-one derivatives and their use for treatment of mammalian infections
WO2013152342A1 (en) 2012-04-06 2013-10-10 OSI Pharmaceuticals, LLC Anti-cancer mtor inhibitor and anti-androgen combination
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US9856320B2 (en) 2012-05-15 2018-01-02 Bristol-Myers Squibb Company Cancer immunotherapy by disrupting PD-1/PD-L1 signaling
HK1214128A1 (zh) 2012-10-05 2016-07-22 Bluelink Pharmaceuticals, Inc. 癌症的治療
US9295731B2 (en) 2013-04-01 2016-03-29 Mark Quang Nguyen Cleavable drug conjugates, compositions thereof and methods of use
AU2015209133B2 (en) 2014-01-24 2019-10-03 AI Therapeutics, Inc. Apilimod compositions and methods for using same
CN107249638B (zh) 2014-11-07 2021-05-14 人工智能治疗公司 阿匹莫德用于治疗肾癌
ES2734081T3 (es) 2014-11-07 2019-12-04 Ai Therapeutics Inc Apilimod para el uso en el tratamiento de melanoma
KR101761573B1 (ko) 2014-12-29 2017-07-26 주식회사 인트론바이오테크놀로지 신규한 장출혈성 대장균 박테리오파지 Ｅｓｃ-ＣＨＰ-1 및 이의 장출혈성 대장균 증식 억제 용도
WO2016126707A1 (en) 2015-02-03 2016-08-11 Lam Therapeutics, Inc. Apilimod compositions and methods for using same
US20180078561A1 (en) 2015-03-31 2018-03-22 Lam Therapeutics, Inc. Active metabolites of apilimod and uses thereof
TWI746449B (zh) 2015-07-20 2021-11-21 美商Ａｉ治療公司 使用阿吡莫德治療癌症之方法
AU2019299234A1 (en) 2018-07-05 2021-01-14 Mayo Foundation For Medical Education And Research PIKfyve inhibitors
US20210077500A1 (en) 2019-09-12 2021-03-18 Al Therapeutics, Inc. Pikfyve inhibitors for cancer therapy

Also Published As

Publication number Publication date
BR112017008799A2 (pt) 2017-12-19
CN107249638A (zh) 2017-10-13
PL3215158T3 (pl) 2019-11-29
RU2017119065A3 (enExample) 2019-06-05
CA2966359A1 (en) 2016-05-12
EP3215158A1 (en) 2017-09-13
EP3581184A1 (en) 2019-12-18
HUE044557T2 (hu) 2019-11-28
MX2017006015A (es) 2017-11-17
US11166944B2 (en) 2021-11-09
EP3581184B1 (en) 2021-02-24
KR20170098812A (ko) 2017-08-30
ES2741399T3 (es) 2020-02-10
IL251905A0 (en) 2017-06-29
US20190201385A1 (en) 2019-07-04
PT3215158T (pt) 2019-08-23
EP3215158B1 (en) 2019-05-08
RU2017119065A (ru) 2018-12-07
JP2017535601A (ja) 2017-11-30
US20200297706A1 (en) 2020-09-24
AU2015342869A1 (en) 2017-06-15
WO2016073877A1 (en) 2016-05-12
US20170333408A1 (en) 2017-11-23
JP6705828B2 (ja) 2020-06-03
MX377593B (es) 2025-03-10
US10206910B2 (en) 2019-02-19
CN107249638B (zh) 2021-05-14
RU2727802C2 (ru) 2020-07-24

Similar Documents

Publication Publication Date Title
IL251630A0 (en) Combined therapy for use in cancer treatment
IL248455A0 (en) igf-1r antibody-drug conjugate and its use for cancer treatment
ZA201607415B (en) Antibody-drug-conjugate and its use for the treatment of cancer
IL251905A0 (en) Epilimod for use in the treatment of kidney cancer
IL258953A (en) Dihydroimidazopyrazinone derivatives are useful for the treatment of cancer
SMT202100115T1 (it) Combinazioni di inibitori di fgfr e cmet per il trattamento del cancro
IL251371A0 (en) Cortexolone 17alpha-benzoate for use in the treatment of tumors
IL276733A (en) Use of Aribolin in cancer treatment
IL248767B (en) Trimethoxyphenyl-benzaimidazole compounds for cancer treatment
IL251903A0 (en) Epilimod for use in the treatment of colon cancer
IL247859A0 (en) Cancer treatment
PL3253208T3 (pl) Terapie kombinowane do zastosowania w leczeniu nowotworu piersi
IL250507A0 (en) Anti-ck8 antibodies for use in cancer therapy
IL252493A0 (en) Compounds for use in the prevention or treatment of cancer
SG11201704684PA (en) Compounds for the treatment of cancer
GB201410695D0 (en) Uses of oligouronates in cancer treatment
GB201411111D0 (en) bis-Pyridazine compounds and their use in treating cancer
HK1237824A1 (en) Combination therapy for use in cancer therapy
ZA201403006B (en) Composition for use in treatment of cancer
EP3125903A4 (en) Method for use of homopiperazinium compounds in the treatment of cancer
GB201417819D0 (en) Agents for cancer therapy
GB201411884D0 (en) Cancer therapy

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed